NCT00112463View on ClinicalTrials.gov

Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 7, 2005

Primary Completion Date

October 23, 2008

Study Completion Date

October 23, 2008

Conditions
Adult Alveolar Soft-part SarcomaAdult AngiosarcomaAdult Epithelioid SarcomaAdult Extraskeletal ChondrosarcomaAdult Extraskeletal OsteosarcomaAdult FibrosarcomaAdult LeiomyosarcomaAdult LiposarcomaAdult Malignant Fibrous HistiocytomaAdult Malignant HemangiopericytomaAdult Malignant MesenchymomaAdult NeurofibrosarcomaAdult RhabdomyosarcomaAdult Synovial SarcomaGastrointestinal Stromal TumorMetastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorRecurrent Adult Soft Tissue SarcomaRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorStage III Adult Soft Tissue SarcomaStage IV Adult Soft Tissue Sarcoma
Interventions
DRUG

romidepsin

DEP is administered at a dose of 13 mg/m2 as a 4-hour intravenous infusion in the outpatient setting.

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00112463 - Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter